Description: SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Home Page: www.sabbiotherapeutics.com
SABS Technical Analysis
2100 East 54th Street North
Sioux Falls,
SD
57104
United States
Phone:
605 679 6980
Officers
| Name | Title |
|---|---|
| Mr. Samuel J. Reich | Exec. Chairman |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, Pres, CEO & Director |
| Ms. Christine E. Hamilton M.B.A. | Co-Founder & Independent Director |
| Dr. Edward D. Hamilton D.V.M. | Co-Founder & Board Observer |
| Mr. Russell P. Beyer C.M.A., M.B.A. | Exec. VP & CFO |
| Dr. Christoph Bausch M.B.A., Ph.D. | Exec. VP & COO |
| Dr. Carlos N. Carillo Ph.D. | Sr. VP of Regulatory Affairs |
| Dr. Alexandra Kropotova M.B.A., M.D. | Exec. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3504 |
| Price-to-Sales TTM: | 1.5056 |
| IPO Date: | 2021-02-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 139 |